AMGEN INC — Director's Dealing 2022

Mar 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2022-03-18

Reporting Person: Bradway Robert A (Director, Chairman, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-18	Common Stock	F	17481	$235.86	Disposed	613316	Direct

Footnotes

F1: These shares include the following RSUs granted under the Company's equity plans: 4,790 RSUs which will vest on 4/27/2022; 10,580 RSUs which vest in installments of 5,211 on 5/3/2022 and 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; and 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 2,773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.